16 August 2016 - The evidence for benefits of adaptive pathways to patients and public health is lacking or contradictory, according to five academics.

In an article published in the BMJ, the five academics from Europe and Canada are critical of the EMA's embracing of a new model of drug testing and marketing called “adaptive pathways”—the brainchild of an industry funded think tank, NEWDIGS (New Drug Development Paradigms), at the Massachusetts Institute of Technology.

The IQWiG has also made public statements that are critical of this drug development model. 

Read BMJ article